Focal Segmental Glomerulosclerosis
Nephrology
7
Pipeline Programs
4
Companies
6
Clinical Trials
3 recruiting
1
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
4
0
2
1
Early DiscoveryClinical DevelopmentMarket
On Market (1)
Approved therapies currently available
Competitive Landscape
4 companies ranked by most advanced pipeline stage
Travere TherapeuticsSAN DIEGO, CA
3 programs2
1
1
sparsentanPhase 31 trial
RE-021Phase 21 trial
SparsentanPhase 21 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
2027
2028
2029
Boehringer IngelheimBI 764198
Travere Therapeuticssparsentan
Akebia TherapeuticsPraliciguat
Travere TherapeuticsSparsentan
AmgenCCX140-B
Travere TherapeuticsRE-021
Clinical Trials (6)
Total enrollment: 838 patients across 6 trials
A Study to Find Out if BI 764198 Helps Adults and Adolescents With a Kidney Condition Called Focal Segmental Glomerulosclerosis (FSGS)
Start: Feb 2026Est. completion: Dec 2029286 patients
Phase 3Recruiting
Study of Sparsentan in Patients With Primary Focal Segmental Glomerulosclerosis (FSGS)
Start: Apr 2018Est. completion: Feb 2026371 patients
Phase 3Active Not Recruiting
A Study of Praliciguat in Participants With Focal Segmental Glomerulosclerosis (FSGS)
Start: Dec 2025Est. completion: Jan 2028
Phase 2Recruiting
Study of Sparsentan Treatment in Pediatrics With Proteinuric Glomerular Diseases
Start: Aug 2021Est. completion: Apr 202767 patients
Phase 2Recruiting
A Study of CCX140-B in Subjects With Primary FSGS and Nephrotic Syndrome
Start: Oct 2018Est. completion: Jun 20205 patients
Phase 2Terminated
Randomized, Double-Blind, Safety and Efficacy Study of RE-021 (Sparsentan) in Focal Segmental Glomerulosclerosis
Start: Mar 2014Est. completion: Mar 2024109 patients
Phase 2Completed
Related Jobs in Nephrology
Thesis work, 60 credits – Establishing In Vitro Models of Mitochondrial Dysfunction in Acute Kidney Injury for Preclinical Drug Discovery
AstraZeneca
Sweden - Gothenburg
1w ago
Associate Director – Nephrology Market Access Strategy
Biogen
Cambridge, MA
1w ago
$164K - $226K/yr
Director, Strategy & Operations-Nephrology Franchise
Biogen
Cambridge, MA
1w ago
$195K - $269K/yr
Medical Science Liaison, CardioRenal - Portland, OR
AstraZeneca
Portland - OR, US
1w ago
Vice President, Head of Renal Sales
Novartis
Field Non-Sales (USA)
1w ago
$274K - $510K/yr
Specialty Account Manager, Nephrology- South Houston, Texas
Amgen
Texas - Houston, US
1w ago
$155K - $184K/yr
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
2 late-stage (Phase 3) programs — potential near-term approvals
3 actively recruiting trials targeting 838 patients
4 companies competing in this space